# Whole-Blood DNA Methylation Analysis Reveals Respiratory Environmental Traits Involved in COVID-19 Severity Following SARS-CoV-2 Infection

- 3 Guillermo Barturen<sup>1</sup>, Elena Carnero-Montoro<sup>1</sup>, Manuel Martínez-Bueno<sup>1</sup>, Silvia Rojo-Rello<sup>2</sup>, Beatriz
- 4 Sobrino<sup>3</sup>, Clara Alcántara-Domínguez<sup>4</sup>, David Bernardo<sup>5,6</sup> and Marta E. Alarcón-Riquelme<sup>1,7</sup>
- <sup>5</sup> <sup>1</sup>GENYO. Center for Genomics and Oncological Research Pfizer/University of Granada/Andalusian
- 6 Regional Government. Granada, Spain.
- <sup>2</sup> Servicio de Microbiología e Inmunología. Hospital Clínico Universitario de Valladolid. Valladolid,
   Spain.
- 9 <sup>3</sup> Servicio de Enfermedades Infecciosas. Hospital Regional de Málaga. Málaga, Spain.
- 10 <sup>4</sup>Lorgen G.P., S.L., Business Innovation Center BIC/CEEL, Technological Area of Health Science,
- 11 Granada, Spain.
- 12 <sup>5</sup>Mucosal Immunology Lab. Unidad de Excelencia Instituto de Biomedicina y Genética Molecular de
- 13 Valladolid (IBGM, Universidad de Valladolid-CSIC). Valladolid, Spain.
- 14 <sup>6</sup>Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas
- 15 (CIBERehd). Madrid, Spain.
- <sup>7</sup>Unit of Inflammatory Chronic Diseases, Institute of Environmental Medicine, Karolinska Institutet,
   Stockholm, Sweden.
- 18 Correspondence: Guillermo Barturen and Marta E. Alarcón-Riquelme: GENYO. Center for
- 19 Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional
- 20 Government, Av de la Ilustración 114, Parque Tecnológico de la Salud, 18016, Granada, Spain.
- 21 guillermo.barturen@genyo.es and marta.alarcon@genyo.es
- 22 Abstract
- 23 SARS-CoV-2 causes a severe inflammatory syndrome (COVID-19) leading, in many cases, to
- 24 bilateral pneumonia, severe dyspnea and in ~5% of these, death. DNA methylation is known to
- 25 play an important role in the regulation of the immune processes behind COVID-19 progression,
- 26 however it has not been studied in depth, yet. In this study, we aim to evaluate the implication of
- 27 DNA methylation in COVID-19 progression by means of a genome-wide DNA methylation analysis
- 28 combined with DNA genotyping.
- 29 The results reveal the existence of epigenomic regulation of functional pathways associated with
- 30 COVID-19 progression and mediated by genetic loci. We found an environmental trait-related

31	signature that discriminates mild from severe cases, and regulates IL-6 expression via the
32	transcription factor CEBP. The analyses suggest that an interaction between environmental
33	contribution, genetics and epigenetics might be playing a role in triggering the cytokine storm
34	described in the most severe cases.
35	Keywords
36	EWAS, SARS-CoV-2, COVID-19, Epigenomics, mQTLs, Autoimmunity
37	Introduction
38	SARS-CoV-2 virus infection has affected millions of people during the last year worldwide. Most
39	infected SARS-CoV-2 individuals remain asymptomatic or with mild symptoms that do not require
40	hospitalization (~81%), while in other, the virus cause a severe inflammatory syndrome called
41	COVID-19 that primarily affects the lungs leading, in many cases, to bilateral pneumonia, severe
42	dyspnea and in ~5% of the cases, death <sup><math>1,2</math></sup> .
43	Several genetics, transcriptomics, and proteomics molecular studies have been performed to date,
44	disentangling important pathogenic molecular mechanisms of the disease (3-14). In summary,
45	SARS-CoV-2 infects the cells expressing surface receptors ACE2 and TMPRSS2 <sup>3</sup> causing cell damage
46	due to its replication and release from the host cell. Then, this process triggers in the surrounding
47	cells the production of pro-inflammatory cytokines and chemokines (including IL-1, IL-6, IL-8, IL-10,
48	TNF and interferon inducible molecules, among others), which establish a pro-inflammatory
49	response mediated by the accumulation of specific immune $cells^4$ . In severe cases, an
50	overexpression of cytokines is produced in lung tissues, known as cytokine storm, thus provoking
51	an over-response of the immune system and causing tissue damage. In the most critical cases, the
52	cytokine storm is spread to other organs leading to multi-organ failure and death. Currently, the

53 molecular mechanisms and the pathophysiology behind COVID-19 progression are largely studied

and well established, but it is still unclear what makes some individuals develop the severe illness. In this sense, underlying genetic variation<sup>5</sup> and different comorbidities have been identified as risk factors, such as diabetes, hypertension, chronic lung disease or even neurological disorders<sup>6,7</sup>. Also life style habits, that might be causing the previous conditions have been also related to COVID-19 illness as obesity or smoking, as well as age, gender or ethnicity<sup>8,9</sup>. However, it is unclear how these comorbidities, environmental and demographic conditions together with genetics, predispose and regulate the molecular mechanisms behind COVID-19 severity.

61 In order to shed light into the molecular relationship between risk factors and the regulation of 62 the mechanisms behind the COVID-19 severity, here we present a DNA methylation EWAS 63 (epigenome wide association analysis) combined with DNA genotyping for 473 and 101 SARS-CoV-64 2 lab positive and negative tested individuals recruited in two independent clinical centers. In 65 addition to the study of the epigenetic regulation of COVID-19 pathogenic mechanisms, the DNA 66 methylation changes associated with COVID-19 progression, and its genetic regulation were put in 67 context by comparing the results with DNA methylation changes occurring in systemic 68 autoimmune diseases (SADs), and with GWAS (genome wide association analysis) and EWAS 69 catalogs that collect multiple traits described as potential COVID-19 severity risk factors.

#### 70 Results

innate

72

### 71 COVID-19 severity relates to impaired blood cell proportions and epigenetic activation of the

immune

response

73	Main blood cell type proportions were deconvoluted from the methylomes, showing a significant
74	increase of neutrophil proportions associated with severity of the disease (Figure 1A and
75	Supplementary Figures 1A and 1B). This imbalanced neutrophil proportion has been already
76	shown to be related to COVID-19 severity progression <sup>10</sup> , and proposed as an early prognostic
77	signature <sup>1</sup> . Besides cell proportion differences, significant differences in age and gender between
78	groups were found in the discovery dataset (Wilcoxon test $p$ -value < 0.05 for age in severe group
79	compared to mild and negative individuals, and Fisher's exact test $p$ -value < 0.05 for gender
80	proportion in severe group compared with mild group). Methylation plates did not show batch
81	bias, being the largest bias between cohorts (Supplementary figures 1B and 1D). Based on these
82	results, differential methylation analyses included as covariates: gender, age and the six major
83	deconvoluted cell proportions.

84 Differential analyses were performed by pairs and longitudinally, after translating groups' severity 85 to a numerical scale (severity analysis, hereafter). We identified 530 CpGs differentially 86 methylated in at least one regression model, and replicated in the validation cohort. Out of these, 87 43 DMCs were found in the severe-negative comparison, 347 in the mild-negative, 20 in severe-88 mild and 257 in the severity analysis (significant DMCs can be consulted in the Supplementary 89 Files). We observed high degree of sharing between DMCs obtained in different comparisons 90 (Figure 1B), except for the severe-mild DMCs which did not overlap with any of the other analyses 91 results'. These specific DMCs from the severe-mild analysis were hypermethylated in the severe 92 condition. Overall, 24 DMCs, annotated into 17 different genes were shared between severe-93 negative, mild-negative and with the severity analyses (Figure 1B and 1C), which give a general

medRxiv preprint doi: https://doi.org/10.1101/2021.11.03.21260184; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

idea of the epigenetic contribution to the progression of COVID-19. Most of the shared signatures
are related to the activation of the viral defense type I interferon inducible genes (OAS1-OAS2
hypermethylated and PARP9-DTX3L, IFIT3, IRF7, TRIM22, MX1 hypomethylated), the
hyperactivation of B and T lymphocytes (CD38, EPSTI1, LAT hypomethylated), and others, as EDC3,
known to interact with ACE2 <sup>11</sup>.

99 DMCs localization enrichment analysis showed that hypermethylated changes related to SARS-100 CoV-2 infection are more prone to occur outside CGIs and in introns and in enhancers for the 101 hypomethylated sites (Supplementary Figure 2A). These genomic regions are known to be hotspots of DNA methylation changes <sup>12</sup>. However, most of the DMCs found in these analyses 102 103 colocalize around the TSS (Transcription Start Site) and/or in the 5'-UTR of the nearest gene 104 (Supplementary Figure 2B), due to the EPIC array probe selection. This probe's preferential 105 location facilitates the interpretation of the results, as hypermethylation and hypomethylation in 106 5'-end regions of the genes is directly related to the inactivation and activation of gene expression, 107 respectively<sup>13</sup>.

108 COVID19 disease DNA methylation changes in neutrophils, B-lymphocytes and CD8+ T-

109 *lymphocytes regulate autoimmune and viral defense related functional pathways* 

Functional enrichment analyses based on *Reactome pathway database* was performed taking into consideration the groups compared and the direction of the effects. An enrichment of hypomethylated signals at interferon-inducible genes, herein called IFN signature, and enrichment of hypermethylated signals at genes involved in FCGR phagocytosis and CD209 signaling (DC-SIGN) was observed when positive SARS-CoV-2 are compared to negative SARS-CoV-2 individuals (Figure 2A). The activation of IFN signature genes is related with an active viral infection and in particular with SARS-Cov-2 infection <sup>10</sup>. However, at DNA methylation level the impaired interferon response

between mild and severe cases found at the transcriptional level <sup>14</sup> cannot be observed (Supplementary Figure 3). This suggests that the exhaustion of the interferon signature might be controlled at a different regulatory level.

120 We performed interaction analysis between deconvoluted cell proportions and severity groups to 121 identify which blood cell type is contributing to the epigenetic signatures. Our results suggest that 122 interferon associated hypomethylation changes were mainly due to neutrophils and CD8+ T-123 lymphocytes (Figure 2B), while hypermethylation changes are primarily related to B-lymphocytes 124 (Figure 2B) which in turn, might be related with the inactivation of CD209 signaling (Figure 2A). 125 CD8+ T-lymphocytes also showed a number of significant hypermethylated interactions (Figure 2B) 126 that may be related with the inactivation of FCGR3A phagocytosis-related genes in these cells 127 (Figure 2A). Lastly, in the severe-mild analysis, methylation changes of the PIP3 activated AKT 128 signaling pathway differentiate severe from mild COVID-19 patients (Figure 2A). Genes related 129 with this pathway are hypermethylated in severe cases compared with mild COVID-19 cases, being 130 CD8+ T-lymphocytes the major contributors to these changes (Figure 2B).

131 Finally, enrichment analyses were performed to assess to which other phenotypes or diseases the 132 COVID-19 DMCs had been associated. For that, we used the information gathered in the EWAS 133 Atlas catalog<sup>15</sup>. Except for severe-mild DMCs, the other 3 comparisons showed DNA methylation 134 changes in CpGs that were previously associated with different autoimmune conditions, allergy 135 conditions, and an asthma related trait (as fractional exhaled nitric oxide test), but also with 136 differential respiratory related environmental exposures (air pollution and polybrominated 137 biphenyl exposure) and/or comorbidities that reflect lifestyle habits as body mass index, smoking 138 or alcohol consumption (Figure 2C).

139 Respiratory environmental related epigenetic changes differentiate severe and mild COVID-

#### 140 19 patients and mild COVID-19 cases from systemic autoimmune disorders

141 Significant DMCs from all the differential analyses performed were clustered together based on 142 their methylation profile grouped by COVID-19 severity and divided into the two recruited cohorts 143 (Figure 3A). Hierarchical clustering reveals that, aside from the significant values obtained in the 144 linear regression models, not all trends of DMCs methylation changes are exactly replicated in 145 both cohorts. Thus, 4 DMC modules were obtained based on the hierarchical clustering where 146 DNA methylation changes were stable: S.Ho, composed by CpGs with a hypomethylation profile 147 along COVID-19 severity; S.He, characterized by a hypermethylation profile along COVID-19 148 severity; M.Ho, in which hypomethylation events are observed in mild as compared with severe 149 cases; and M.He, in which hypermethylation occurs in mild as compared with severe cases.

150 In summary, *Reactome* pathway enrichment analysis done on the 4 modules (Figure 3B) replicated 151 the previous enrichments found for the DMCs grouped in the linear regression analysis (Figure 152 2A). Interestingly, a new additional pathway appeared to be enriched in the S.He module, related 153 with potential therapeutics for SARS, which suggests that several of the proposed therapeutic 154 targets for SARS infection are based on the activation of hypermethylated molecular pathways 155 during the course of the COVID-19 disease. In order to validate the activation or inactivation of the 156 enriched pathways revealed by means of the DNA methylation changes, *Reactome* pathways 157 activity was estimated based on single-cell RNA-Seq information from publicly available analyses 158 <sup>16,17</sup>. The analysis was focused on the cell-types that mostly contribute to the DNA methylation 159 changes: CD8+ T-lymphocytes, B-lymphocytes and neutrophils, as revealed from the interaction 160 results (Figure 2B). In general, molecular pathway activities follow the DNA methylation changes at 161 early sampling time points, which correspond to our recruited cohorts. This is, that pathways that 162 show hypomethylation in certain group(s) of individuals coincide with a higher transcriptome

medRxiv preprint doi: https://doi.org/10.1101/2021.11.03.21260184; this version posted November 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

activity compared with the hypermethylated groups, at least in the cell-types in which the change has been predicted to be occurring (Supplementary Figure 4). For example, the FCGR3A phagocytosis pathway (enriched in S.He module) activity is decreased with the severity of the disease in CD8+ T-lymphocytes, while the interferon signaling (enriched in S.Ho module) activity is increased with the severity. Certainly, at the transcriptome level, the interferon exhaustion signature associated with severe cases, not previously seen at the DNA methylation level (Supplementary Figure 3), can be appreciated for B-lymphocytes and CD8+ T-lymphocytes.

On the other hand, *EWAS Atlas catalog* enrichments were performed by modules, revealing that autoimmune and asthma related traits are mostly enriched in S.Ho and S.He modules, while the differential respiratory environmental related traits were mostly enriched in the M.He module. This M.He module differentiates severe and mild COVID-19 cases, suggesting an important contribution of the respiratory environmental exposure to the progression of COVID-19 disease, at least at the DNA methylation level.

176 TFBS motif analysis reveals specific TFBS motifs enriched for the different modules (Figure 3D). 177 S.Ho module was mainly enriched in interferon regulatory TFBSs, in line with the *Reactome* 178 pathway enrichment results, and among the other results stands out the enrichment of the CEBP 179 motif in M.He module. CEBP is a transcription factor related with the inflammatory immune 180 response by cooperating with and stimulating the transcription of different pro-inflammatory 181 cytokines<sup>18</sup>, among others, IL-6.

Given the potential relationship of COVID-19 affected molecular pathways and autoimmune disorders, DNA methylation profiles were compared between COVID-19 and the PRECISESADS collection <sup>19</sup>, which includes DNA methylation information from seven SADs (Figure 3E). Both, severe and mild related DNA methylation changes correlate with systemic autoimmune disorders

186 for S.He module, with a slightly higher intensity in severe COVID-19 patients. S.Ho module 187 correlations are also significantly positive, except for RA and SSc comparison with mild cases, 188 which present no significant correlations. RA and SSc patients are known not to be frequently 189 expressing the IFN signature, enriched in S.Ho module<sup>20</sup>. Thus, this result might be related with 190 the presence of two signatures contributing to this module, one related with the interferon, which 191 highly correlates with most interferon related SADs, and another one that correlates between 192 severe, RA and SSc. In order to further investigate the differential correlation between SADs in this 193 particular module, strongest hypomethylated CpGs in interferon related SADs and COVID patients 194  $(\log FC < -0.25)$  corresponding with IFN signature genes, were removed from the correlation 195 analyses (annotated in TRIM22-TRIM5, PARP9-DTXL3, RUNX1, IFIT3, IRF7, EPSTI1, MX1 and ADAR 196 genes). The correlation without these CpGs shows a dramatic reduction for interferon related 197 SADs, while RA and SSc correlations with severe cases are preserved (Supplementary Figure 5). 198 This means that the remaining CpGs (annotated in genes as CCDC61, CD38, FAM38A, LAT, TREX1 199 or NFAT5, among others) differentially contribute to COVID19 progression similarities with SADs, 200 some of them regulating the activation and differentiation of T and B lymphocytes. On the other 201 hand, M.He module shows a strong correlation for severe and a strong anti-correlation with mild 202 cases, thus differentiating mild cases from SADs. Lastly, M.Ho correlation results do not show 203 significant correlation values.

#### 204 DNA methylation changes that differentiate mild and severe COVID19 cases show low

205 genetic contribution and mQTLs enriched in SNPs associated with environmental traits

As the DNA methylation modules that mostly differentiate severe and mild cases (M.He) were mainly associated with environmental traits, we next interrogated whether there is genetic contribution behind these epigenetic changes, and how genetics contribute to the DNA methylation modules. In this sense, DNA methylation heritability was calculated for each CpG in

210 the modules. Two independent methods showed high agreement in heritability calculation 211 (Supplementary Figure 6A), so for the subsequent analysis variance decomposition model was 212 selected. Genetic contribution to methylation variability was shown to contribute differentially 213 between modules, being larger in S.Ho and S.He than in M.Ho and M.He modules (Figure 4A). This 214 is in agreement with the higher environmental contribution to M.He shown by EWAS traits 215 enrichments. Additionally, covariates as SARS-CoV-2 infection, age and gender were shown not to 216 modify the genetic contribution to DNA methylation changes (Supplementary Figure 6B). S.Ho and 217 S.He modules were the most affected by SARS-CoV-2 infection, while M.Ho and M.He variation 218 might be driven by other covariates or environmental factors that, unfortunately, were not 219 recorded in these cohorts (Supplementary Figure 6C).

220 In order to further investigate the genetic contribution to the DNA methylation changes observed 221 during COVID-19 progression, cis-mQTLs (methylation quantitative trait loci) were assessed 222 (significant results can be consulted in Supplementary Files). Linear regression models were fit 223 independently for each severity group (FDR < 0.05 for at least one group), showing that around 224 50% of the CpGs in each module were associated with at least one SNP (Supplementary Figure 6D). 225 In total, 7899 unique mQTLs were found to be significant for at least one of the severity groups, 226 composed of 7548 SNPs and 175 CpGs (out of 352 DMCs) with an average of 45±84 SNPs by CpG, 227 what indicates that almost half of the DNA methylation changes found are being regulated by 228 large blocks of SNPs in cis. mQTLs were classified according to the SNP-CpG association 229 significance by severity groups, then labeling for example: a mQTL as mild specific, when the 230 significant association (p-value < 0.05) was only found in COVID-19 mild cases, or positive specific, 231 when both mild and severe cases showed a significant association (Figure 4B). mQTLs classification 232 showed a differential genetic regulation by module (Figure 4C), where methylation changes, which 233 follows COVID-19 progression (S.Ho and S.He modules), were enriched in mQTLs shared by all the

234 severity groups (common mQTLs), which means that the genetic regulation of these DNA 235 methylation changes does not depend on the severity of the disease but are a general regulatory 236 mechanism. On the other hand, mQTLs in M.Ho and M.He modules were mostly identified as 237 group-specific mQTLs, with a large fraction of mild and positive specific in M.He module, and mild, 238 severe and severe/negative specific in M.Ho module. The genetic regulation specificity of M.He is 239 also supported by significant differences of the normalized MAF (each group minor allele 240 frequency divided by all groups' minor allele frequency) for the mild and positive specific mQTLs 241 (Figure 4D). MAF in positive specific mQTLs showed a higher frequency in mild and severe groups 242 compared to negative individuals, while the mild specific mQTLs showed a higher MAF in mild 243 cases. Surprisingly, MAF differences were found between mild compared to severe and negative 244 individuals for common and positive specific mQTLs in S.Ho modules, which might indicate a 245 differential genetic regulation also for mild individuals for the S.Ho signature (Figure 4D).

246 The enrichment of the significant mQTLs by module were tested for SNPs previously known to be 247 associated with different traits. In this sense, mQTLs trait enrichments were performed considering the GWAS catalog database<sup>21</sup> and the COVID-19 associated SNPs from the COVID-19 248 249 Host Genetics Initiative <sup>5,22</sup>. The results showed a strong enrichment of SNPs associated with 250 COVID-19 and interferon related autoimmune diseases (Systemic Lupus Erythematosus) in the 251 mQTLs regulating the S.Ho module and SNPs associated with non-interferon related autoimmune 252 diseases in the S.He module (Figure 4E). On the other hand, M.He mQTLs were enriched with 253 environmental related SNPs (Figure 4E), mimicking the enrichments shown above for the EWAS 254 catalog. Interestingly, two different COVID-19 GWAS regions are regulating the S.Ho and S.He 255 modules. In the case of the S.Ho module, its *cis*-mQTLs are composed of SNPs at 3p21.31 GWAS 256 peak <sup>22,23</sup>, found to be associated in severe, hospitalized and in general SARS-CoV-2 lab positive 257 tested patients compared with the general population. While S.He module is enriched in SNPs

located at 8q24.13 GWAS peak <sup>22</sup>, only found to be statistically significant in hospitalized COVID-19
 patients compared to general population <sup>22</sup>.

260 Discussion

The EWAS of SARS-CoV-2 infection reveals a DNA methylation regulation of important functional pathways related with COVID-19 progression and specific epigenetic differences between severe and mild patients. Differentially methylated CpG sites were shared between severe and mild cases, mainly associated with the activation of interferon signaling pathway and the hyper-activation of B and T lymphocytes. These pathways have been previously associated with COVID-19 severity in transcriptome studies <sup>10,24</sup>, showing in this study that the regulation of these pathways is being mediated by epigenetic changes at the promoter level of the implicated genes (Figure 1).

268 Apart from the DMCs shared between the differential analyses, the pathways enrichment analysis 269 for the individual regression models showed the epigenetic deregulation of specific pathways as 270 CD209 signaling (DC-SIGN), FCGR phagocytosis pathway and AKT signaling in specific blood cell-271 types (Figure 2). CD209 is primarily expressed in dendritic cells and B-lymphocytes, and its 272 interaction with CD209L, expressed in SARS-CoV-2 target tissue endothelial cells, has been shown to facilitate the virus entry <sup>25</sup>. Thus, CD209 signaling hypermethylation might be playing a 273 274 protective role during SARS-CoV-2 infection. Additionally, CD209 activation has been shown to promote B-lymphocyte survival <sup>26</sup>. However, this process does not seem to be occurring in SARS-275 276 CoV-2 infection as shown by the B-lymphocyte depletion observed in the deconvolution analysis 277 (Figure 1A). FCGR phagocytosis pathway is involved in the antibody-antigen complex clearance and 278 the antibody dependent cellular mediated cytotoxicity. CD8+ T-lymphocytes expressing FCGR3A (CD16) have been described to acquire natural killer (NK) cell-like functional properties, thus 279 contributing to their cytotoxic functionality, increased in chronic hepatitis C virus infections <sup>27</sup>. 280

281 Recently, suppression of cytotoxic activity has been described on CD8+ T-lymphocytes and NK-cells 282 from severe COVID-19 patients <sup>28</sup>, which in the light of our DNA methylation results might be 283 impaired because of the DNA hypermethylation of genes of the FCGR3A phagocytosis pathway. 284 Based on our results, these two pathways seem to be associated with the progression of the 285 disease, showing significant DNA methylation changes along its course. On the other hand, gene 286 promoters related with the AKT signaling pathway were specifically found to be differentially 287 methylated when compared severe and mild cases (hypomethylated in mild), thus differentiating 288 at the epigenome level severe from mild SARS-CoV-2 infected patients. AKT signaling in CD8+ T-289 lymphocytes is critical for the effector-memory transition of this cell-type<sup>29</sup>, thus impairing the 290 protective immune secondary response and potentially contributing to the worst outcome. Other 291 important genes, not annotated in these pathways, were found to show methylation differences, 292 as for example EDC3. Interestingly, hypermethylation of EDC3 in severe cases might be mediating 293 the overexpression of ACE2 protein in SARS-CoV-2 patients, thus favoring infection  $^{3}$ . EDC3 is a 294 component of a decapping complex that promotes removal of the monomethylguanosine (m7G) 295 cap from mRNAs, being an important protein during mRNA degradation, and its interaction with 296 ACE2 has been experimentally validated and shown with STRING interaction network <sup>30</sup>.

297 In addition to the COVID-19 EWAS results, DMCs were grouped by hierarchical clustering and 298 filtered by cohorts' similarity (Figure 3). Four modules of co-regulated CpGs were found, where 299 three of them are enriched in the functional pathways previously described. CD209 and FCGR 300 phagocytosis pathways (S.He module) are hypermethylated with the severity of the disease, and 301 both severe and mild cases, perfectly correlate with DNA methylation changes observed in SADs. 302 Hypomethylation along COVID-19 severity module (S.Ho) was found to be composed by two 303 signatures, an interferon related signature which correlates with interferon related systemic 304 autoimmune diseases (as MCTD, SLE or pSjS) at both severe and mild cases, and a T and B

305 lymphocyte activation signature, which correlates mainly with non-interferon related SADs (RA 306 and SSc) for severe cases. The AKT signaling pathway was also represented in the mild 307 hypomethylated module (M.Ho). The fourth module, hypermethylated in mild cases (M.He), is of 308 particular interest. It perfectly discriminates between severe and mild COVID-19 cases, and severe 309 DNA methylation changes are highly correlated with autoimmune conditions. Additionally, and in 310 contrast to the other CpG modules, its CpGs have not been related with autoimmune conditions 311 but with respiratory environmental conditions. Further analyses on this module revealed an 312 enrichment in CEBP binding sites (Supplementary Figure 6C). CEBP transcription factor has an 313 important role regulating IL-6 and IL-1 expression, whose elevated levels have been associated 314 with severe complications of COVID-19 disease <sup>4</sup>. This result shows a reduced activity of CEBP 315 binding sites in mild cases compared with the severe ones, in a module where DMCs are enriched 316 in respiratory environmental traits. Altogether, our results suggest the existence of a relationship 317 between environmental exposure and the cytokine storm associated with the most critical 318 outcomes of COVID-19 disease.

The genetic regulation of COVID19 associated DNA methylation changes were also studied, finding important differences between modules (Figure 4). In addition to a lesser genetic contribution to the DNA methylation changes in M.Ho and M.He modules, the mQTLs associated to these modules showed more group specificity than S.Ho and S.He modules. Importantly, *GWAS catalog* enrichments for the mQTLs showed again a predominance of environmental traits related SNPs for the M.He module, which reinforces the idea of the importance of the environmental exposure during the regulation of the DNA methylation changes in this module.

This study is the first in depth large EWAS comparing SARS-CoV-2 RT-PCR positive and negative individuals. The results show a large epigenetic regulation of autoimmune related functional pathways during COVID-19 progression that differentiate severe from mild COVID-19 cases. Some

329 of these autoimmune related pathways presented DNA methylation differences between severe 330 and mild cases with less genetic contribution, but with higher genetic specificity than changes that 331 progress with the severity of the disease. Interestingly, these specific epigenetic changes were 332 mainly related, in terms of DNA methylation sites and SNPs regulating these sites, with 333 environmental traits. Thus, in the light of the results, the interaction between specific genetic 334 changes and different environmental exposure or life habits might be deregulating, via DNA 335 methylation changes, autoimmune related functional pathways which are related with the 336 worsening of SARS-CoV-2 infection. Despite the relationship between environmental exposure and 337 COVID-19 severity has been suggested in previous epidemiological studies, this is the first time 338 that this relationship is supported by genetic and epigenetic molecular information, thus, 339 contributing to the understanding of the disease at the molecular level. Of special importance is 340 the association of these environmental related DNA methylation changes with the cytokine storm 341 typical of the most severe COVID-19 cases.

342 Methods

343 Study design and cohorts

344 Whole blood samples from SARS-CoV-2 RT-PCR negative (101) and positive lab tested individuals 345 (473) were obtained from two clinical centers (Hospital Clínico Universitario de Valladolid, 346 discovery cohort and Hospital Regional Universitario de Málaga, validation cohort). The regional 347 ethical committees from Andalucía (Comité Coordinador de Ética de la Investigación Biomédica de 348 Andalucía) and from Valladolid (COMITÉ DE ÉTICA DE LA INVESTIGACIÓN CON MEDICAMENTOS 349 ÁREA DE SALUD VALLADOLID) approved the protocols and gave their ethical approval for this 350 study and all recruited individuals signed the informed consent prior to recruitment. Whole blood 351 was sampled upon arrival to the emergency ward, within a week after first symptoms. Discovery

and validation cohorts were recruited between March-April 2020 and August-October 2020, respectively. Positive individuals were divided into: severe (WHO 5-7), if they needed invasive respiratory support, ICU admission and/or died due to SARS-CoV-2 complications, and mild (WHO 2-4), if patients did not develop severe COVID-19 related symptoms. Severity groups between cohorts were gender balanced, but slightly significant differences were found in terms of age (Table 1).

358 Genomic Analysis

359 DNA extraction

360 DNA was extracted from whole blood samples by means of the *QIAamp DNA Blood Mini* kit and 361 the automatic platform *QIAcube Connect*. Afterwards, DNA quality was validated and normalized 362 using the *NanoDrop 2000c* and the *Qubit4*.

363 Genotyping

364 DNA was normalized to 200-400ng and genotyped with Illumina's Infinium GSA-24.v3.0 BeadChip, 365 following manufacturer's recommendations. Markers with genotyping rate > 99%, minor allele 366 frequency > 1% and a p-value for Hardy-Weinberg Equilibrium > 1e-6 were selected. Samples 367 showing genotyping rate < 98%, inconsistencies between reported and genetic sex and extreme 368 heterozygosity values (-0.2 < Fhet < 0.2) were eliminated. The kinship coefficient was calculated 369 for each pair of samples and one member of each pair with a value >= 0.2 was removed. Based on 370 a set of Ancestry Informative Markers (markers which maximize the allelic frequencies across 371 1000Genomes populations), individuals with non-European ancestry components were 372 eliminated. The resulting dataset from this quality control process was imputed in the Michigan Imputation Server <sup>31</sup>, using Minimac4 and 1000Genomes as reference panel <sup>32</sup>. After subsequent 373 374 filtering of the imputation result we obtained a working dataset consisting of 504 samples and

375 more than 9.5 million markers. Quality control of the genotyped data was performed with *Plink2.0* 376 <sup>33</sup>.

#### 377 Methylome profiling

378 DNA methylation information was profiled with the *Illumina's Infinium MethylationEPIC BeadChip*, 379 after sample normalization to 500ng and bisulfite conversion with EZ-96 DNA Methylation Kit, as 380 recommended by the manufacturer. Methylomes were quality controlled by genotype 381 concordance (>= 0.8) using shared SNP probes between platforms (genotypes were extracted after 382 imputation but without post filtering), gender prediction agreement (outliers > 5 standard 383 deviations), signal from noise detection p-value < 0.1 and minimum number of beads (>3) that 384 passed the detection p-value, the last two criteria were applied for both probes and samples. 385 Additionally, sexual chromosomes, cross-reactive probes and probes with overlapping SNPs from dbSNP v.147<sup>34</sup> were discarded. Methylation beta values were normalized by means of functional 386 387 normalization. After guality control, 574 samples and 768,067 probes were selected. The entire process was performed with *minfi and meffil R packages*<sup>35,36</sup>. 388

389 Statistical Analysis

#### 390 Deconvolution of cell proportions

391 Iterative hierarchical procedure implemented in *EpiDISH R package* <sup>37</sup> was used to estimate the 392 main blood cell type proportions from methylome information with the robust partial correlation 393 method <sup>38</sup>. Whole blood cell type reference panel includes: neutrophils, monocytes, B-394 lymphocytes, CD4+ T-Lymphocytes, CD8+ T-Lymphocytes and natural killer cells.

### 395 Differential and interaction analysis

396 Differential methylation analyses were performed by linear regression models, including gender,

397 sex and deconvoluted cell-proportions as covariates. Linear regression models including

interaction terms between the groups of interest and deconvoluted cell proportions, were used to estimate the specific cell type(s) where the methylation changes occur, as proposed by Zheng et al  $400^{39}$ . Methylation changes and interactions were considered significant at nominal *p*-values below 0.01 in discovery and validation datasets, and below a genome wide significant level of 5e-8 in the meta-analysis of both cohorts. Meta-analyses were performed with the restricted maximum likelihood (REML) method and fixed effects implemented in *metafor R package*<sup>40</sup>.

#### 404 Enrichment, correlation and co-localization analysis

405 DMCs (Differentially methylated CpGs) and/or genes that co-localized with them, based on the 406 Illumina annotation (iIm10b4.hg19 R package), were analyzed. Functional pathway analysis were performed against Reactome Pathway Database <sup>41</sup> using ReactomePA R package <sup>42</sup>. EWAS trait 407 enrichments were tested within the EWAS Atlas database <sup>15</sup>. PRECISESADS methylomes <sup>19</sup> from 408 seven SADs (SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; pSjS, primary Sjögren's 409 410 syndrome; SSc, systemic sclerosis; MCTD, mixed connective tissue disease; PAPS, primary anti-411 phospholipids syndrome and UCTD, undifferentiated connective tissue disease) and healthy 412 controls were used to compare with COVID-19 epigenetic changes. TFBS (transcription factor binding site) motif enrichment analysis was performed with *HOMER software*<sup>43</sup> using a size of 200 413 414 nucleotides and including as background the CpGs interrogated with the EPIC array.

#### 415 Molecular pathway activity analysis

Single-cell RNA-Seq datasets were obtained from *Schulte-Schrepping et al.* <sup>17</sup> (BD Rhapsody system dataset, including neutrophils) and *Ren et al.* <sup>16</sup> (10x Genomics chromium dataset, not including neutrophils). Cells from both datasets were selected based on: mitochondrial read percentage < 5%, hemoglobin read percentage < 1%, number of reads > 500 and < 6000, and number of genes profiled between 200 and 2000. After the quality criteria filtering, almost all non-neutrophil cells</p>

421 were lost from Schulte-Schrepping et al. dataset. Thus, CD8+ T-lymphocytes and B-lymphocytes 422 were analyzed from the Ren et al. dataset and neutrophils from the Schulte-Schrepping et al.. 423 Individuals were classified as early or late based on Schulte-Schrepping et al. definition (late, 424 sampling >11 days after first symptoms) and authors 'defined cell-type annotation was used to 425 select two subsamples of 2500 cells for each cell-type (500 cells per severity group and onset 426 category). Molecular pathway activity values were estimated by means of ssgsea algorithm implemented in escape R package <sup>44</sup>. HLA and Immunoglobulin genes were removed from the 427 428 *Reactome* pathways before activity calculation.

#### 429 Genetic statistical analyses

430 Overall genetic contribution to DNA methylation changes (heritability, h2) was estimated by means of two models: one based on variance decomposition analysis from a linear mixed-model <sup>45</sup> 431 and the other one using the diagonalization trick <sup>46</sup>. The kinship matrix for the former model was 432 433 calculated by means of *popkin R package*<sup>47</sup>, while for the diagonalization trick estimation, *gaston* 434 *R* package recommendations were followed  $^{46}$ . Methylation quantitative trait loci (mQTLs) 435 analyses were performed using the matrix-eQTL R package <sup>48</sup>. We applied a linear regression 436 model that tests the additive effects of allele dosages for each genetic variant on the DNA 437 methylation levels, while correcting for age, sex, the deconvoluted cell proportions and the first 438 two genetic principal components. We restricted analysis to *cis*-mQTL mapping (maximum 439 distance between CpG and SNPs of 1Mb) and SNPs with minor allele frequencies (MAF) > 0.05. cis-440 mQTL analyses were performed independently on the different severity groups, using a FDR < 0.05 441 as significance threshold. Significant mQTLs were classified as common or specific QTLs based on 442 whether the association nominal p-values were below 0.05 for all the severity groups or not. Then 443 classifying non-common QTLs based on the severity groups that pass the threshold (QTL effects 444 were took into consideration what might result on shared significant QTLs between groups but

445	with opposite effects). mQTLs enrichments were tested against SNP associated traits from the
446	GWAS catalog database <sup>21</sup> expanded with COVID-19 Host Genetics Initiative results <sup>5,22</sup> . GWAS
447	catalog traits were selected based on studies with a replication cohort and at least 50 SNPs below
448	the genomic significant threshold ( $p$ -value < 5e-8). Traits annotation into mQTLs were performed
449	based on linkage-disequilibrium blocks by means of PLINK1.9 software 33,49, applying blocks
450	function <sup>50</sup> default parameters in a maximum window size of 1MB.

- 451 Data availability
- 452 Genotypes summary statistics can be accessed through COVID-19 Host Genetic Initiative web page
- 453 (<u>https://www.covid19hg.org/</u>), included in project "*Determining the Molecular Pathways and*
- 454 Genetic Predisposition of the Acute Inflammatory Process Caused by SARS-CoV-2 (SPGRX)".
- 455 Methylation data are available from Gene Expression Omnibus (GEO) at XXXXXXXX.
- 456 References
- 457 1 Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. 458 The New England 382, 1708-1720, journal of medicine 459 doi:10.1056/NEJMoa2002032 (2020). 460 Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in 2 461 Wuhan, China. Lancet 395, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020). 462 Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 3 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181, 271-280 e278, 463 doi:10.1016/j.cell.2020.02.052 (2020). 464 Del Valle, D. M. et al. An inflammatory cytokine signature predicts COVID-19 465 4 severity and survival. Nature medicine 26, 1636-1643, doi:10.1038/s41591-020-466 1051-9 (2020). 467 Initiative, C.-H. G. The COVID-19 Host Genetics Initiative, a global initiative to 468 5 469 elucidate the role of host genetic factors in susceptibility and severity of the SARS-470 CoV-2 virus pandemic. European journal of human genetics : EJHG 28, 715-718, doi:10.1038/s41431-020-0636-6 (2020). 471 472 Harrison, S. L., Fazio-Eynullayeva, E., Lane, D. A., Underhill, P. & Lip, G. Y. H. 6 Comorbidities associated with mortality in 31,461 adults with COVID-19 in the 473 474 United States: A federated electronic medical record analysis. *PLoS medicine* 17, 475 e1003321, doi:10.1371/journal.pmed.1003321 (2020). Booth, A. et al. Population risk factors for severe disease and mortality in COVID-476 7 477 19: A global systematic review and meta-analysis. PloS one 16, e0247461, 478 doi:10.1371/journal.pone.0247461 (2021).

- Rossen, L. M., Branum, A. M., Ahmad, F. B., Sutton, P. & Anderson, R. N. Excess
  Deaths Associated with COVID-19, by Age and Race and Ethnicity United States,
  January 26-October 3, 2020. *MMWR*. *Morbidity and mortality weekly report* 69,
  1522-1527, doi:10.15585/mmwr.mm6942e2 (2020).
- 483 9 Li, X. *et al.* Clinical determinants of the severity of COVID-19: A systematic
  484 review and meta-analysis. *PloS one* 16, e0250602,
  485 doi:10.1371/journal.pone.0250602 (2021).
- 486 10 Lucas, C. *et al.* Longitudinal analyses reveal immunological misfiring in severe
  487 COVID-19. *Nature* 584, 463-469, doi:10.1038/s41586-020-2588-y (2020).
- 488 11 Szklarczyk, D. *et al.* STRING v11: protein-protein association networks with
  489 increased coverage, supporting functional discovery in genome-wide experimental
  490 datasets. *Nucleic acids research* 47, D607-D613, doi:10.1093/nar/gky1131 (2019).
- 49112Ziller, M. J. *et al.* Charting a dynamic DNA methylation landscape of the human492genome. *Nature* **500**, 477-481, doi:10.1038/nature12433 (2013).
- Martino, D. & Saffery, R. Characteristics of DNA methylation and gene expression
  in regulatory features on the Infinium 450k Beadchip. *bioRxiv*, 032862,
  doi:10.1101/032862 (2015).
- Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* 369, 718-724, doi:10.1126/science.abc6027 (2020).
- 49915Li, M. *et al.* EWAS Atlas: a curated knowledgebase of epigenome-wide association500studies. *Nucleic acids research* 47, D983-D988, doi:10.1093/nar/gky1027 (2019).
- 50116Ren, X. et al. COVID-19 immune features revealed by a large-scale single-cell502transcriptome atlas. Cell 184, 1895-1913 e1819, doi:10.1016/j.cell.2021.01.053503(2021).
- 50417Schulte-Schrepping, J. et al. Severe COVID-19Is Marked by a Dysregulated505MyeloidCellCompartment.Cell182,1419-1440e1423,506doi:10.1016/j.cell.2020.08.001 (2020).
- Matsusaka, T. *et al.* Transcription factors NF-IL6 and NF-kappa B synergistically
  activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. *Proceedings of the National Academy of Sciences of the United States of America*90, 10193-10197, doi:10.1073/pnas.90.21.10193 (1993).
- 511 19 Barturen, G. *et al.* Integrative Analysis Reveals a Molecular Stratification of
  512 Systemic Autoimmune Diseases. *Arthritis & rheumatology*, doi:10.1002/art.41610
  513 (2020).
- 51420Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases.515Nature reviews. Rheumatology 14, 214-228, doi:10.1038/nrrheum.2018.31 (2018).
- 516 21 Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide
  517 association studies, targeted arrays and summary statistics 2019. *Nucleic acids*518 *research* 47, D1005-D1012, doi:10.1093/nar/gky1120 (2019).
- 51922Ganna, A. Mapping the human genetic architecture of COVID-19 by worldwide520meta-analysis.medRxiv,2021.2003.2010.21252820,521doi:10.1101/2021.03.10.21252820 (2021)
- 521 doi:10.1101/2021.03.10.21252820 (2021).
- 52223Ellinghaus, D. *et al.* The ABO blood group locus and a chromosome 3 gene cluster523associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide524associationanalysis.525doi:10.1101/2020.05.31.20114991 (2020).

526	24	Chen, Z. & John Wherry, E. T cell responses in patients with COVID-19. Nature
527		reviews. Immunology 20, 529-536, doi:10.1038/s41577-020-0402-6 (2020).
528	25	Amraie, R. et al. CD209L/L-SIGN and CD209/DC-SIGN act as receptors for
529		SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and
530		endothelial cells. <i>bioRxiv</i> , doi:10.1101/2020.06.22.165803 (2020).
531	26	Valentin, A. J. & Díaz, G. Y. CD209 activation promotes survival of lymphoblastic
532		human B cells. The Journal of Immunology 202, 123.125-123.125 (2019).
533	27	Bjorkstrom, N. K. et al. Elevated numbers of Fc gamma RIIIA+ (CD16+) effector
534		CD8 T cells with NK cell-like function in chronic hepatitis C virus infection.
535		Journal of immunology 181, 4219-4228, doi:10.4049/jimmunol.181.6.4219 (2008).
536	28	Yao, C. et al. Cell-Type-Specific Immune Dysregulation in Severely Ill COVID-19
537		Patients. Cell reports 34, 108590, doi:10.1016/j.celrep.2020.108590 (2021).
538	29	Rogel, A. et al. Akt signaling is critical for memory CD8(+) T-cell development
539		and tumor immune surveillance. Proceedings of the National Academy of Sciences
540		of the United States of America <b>114</b> . E1178-E1187. doi:10.1073/pnas.1611299114
541		(2017).
542	30	Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated
543		over the tree of life. <i>Nucleic acids research</i> <b>43</b> . D447-452. doi:10.1093/nar/gku1003
544		(2015)
545	31	Das S et al Next-generation genotype imputation service and methods <i>Nature</i>
546	01	genetics <b>48</b> 1284-1287 doi:10.1038/ng 3656 (2016)
547	32	Genomes Project $C$ et al. A global reference for human genetic variation Nature
548	52	<b>526</b> 68-74 doi:10.1038/nature15393 (2015)
549	33	Chang C C et al. Second-generation PLINK: rising to the challenge of larger and
550	55	richer datasets <i>GigaScience</i> <b>4</b> 7 doi:10.1186/s13742-015-0047-8 (2015)
551	34	Sherry, S. T., Ward, M. & Sirotkin, K. dbSNP-database for single nucleotide
552	0.	polymorphisms and other classes of minor genetic variation. Genome research 9
553		677-679 (1999).
554	35	Fortin J. P. Triche, T. J. Jr. & Hansen, K. D. Preprocessing, normalization and
555	50	integration of the Illumina HumanMethylationEPIC array with minfi
556		<i>Bioinformatics</i> <b>33</b> , 558-560, doi:10.1093/bioinformatics/btw691.(2017)
557	36	Min I L. Hemani G. Davey Smith G. Relton C. & Suderman M. Meffil:
558	50	efficient normalization and analysis of very large DNA methylation datasets
559		<i>Bioinformatics</i> <b>34</b> 3983-3989 doi:10.1093/bioinformatics/btv476 (2018)
560	37	Zheng S C et al EniDISH web server: Enigenetic Dissection of Intra-Sample-
561	51	Heterogeneity with online GUL <i>Bioinformatics</i> doi:10.1093/bioinformatics/btz833
562		(2010)
563	38	(2017). Teschendorff A E Breeze C E Zheng S C & Beck S A comparison of
561	50	reference based algorithms for correcting cell type beterogeneity in Enigenome
565		Wide Association Studios <i>BMC</i> bioinformatics <b>18</b> 105 doi:10.1186/s12850.017
566		1511 5 (2017)
567	20	Then S C Press C E Peak S & Teschanderff A E Identification of
569	39	Zheng, S. C., Dieeze, C. E., Beck, S. & Teschendonn, A. E. Identification of differentially mathylated call types in onigenome wide association studies. <i>Nature</i>
JU8 560		methods 15, 1050, 1066, doi:10, 1028/s/1502, 018, 0212, w (2018)
309 570	40	<i>memous</i> 15, $1039-1000$ , $u01.10.1050/841392-018-0215-X$ (2018).
570 571	40	v rechtoauer, w. Conducting wieta-Analyses in K with the metafor Package. Journal
5/1		oj sialistical software; vol 1, Issue 5 (2010) (2010).

- Jassal, B. *et al.* The reactome pathway knowledgebase. *Nucleic acids research* 48, D498-D503, doi:10.1093/nar/gkz1031 (2020).
- 574 42 Yu, G. & He, Q. Y. ReactomePA: an R/Bioconductor package for reactome 575 pathway analysis and visualization. *Molecular bioSystems* **12**, 477-479, 576 doi:10.1039/c5mb00663e (2016).
- Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors
  prime cis-regulatory elements required for macrophage and B cell identities. *Molecular cell* 38, 576-589, doi:10.1016/j.molcel.2010.05.004 (2010).
- 580 44 Borcherding, N. & Andrews, J. escape: Easy single cell analysis platform for 581 enrichment, 2021).
- 582 45 Ziyatdinov, A. *et al.* lme4qtl: linear mixed models with flexible covariance structure
  583 for genetic studies of related individuals. *BMC bioinformatics* 19, 68,
  584 doi:10.1186/s12859-018-2057-x (2018).
- Manipulation of genetic data (SNPs). Computation of GRM and dominance matrix,
  LD, heritability with efficient algorithms for linear mixed model (AIREML). (46th
  European Mathematical Genetics Meeting (EMGM) 2018, Cagliari, Italy, April 1820, 2018, 2018).
- 589 47 Ochoa, A. & Storey, J. D. Estimating FST and kinship for arbitrary population 590 structures. *PLoS genetics* **17**, e1009241, doi:10.1371/journal.pgen.1009241 (2021).
- 591 48 Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
  592 *Bioinformatics* 28, 1353-1358, doi:10.1093/bioinformatics/bts163 (2012).
- 49 Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population594 based linkage analyses. *American journal of human genetics* 81, 559-575,
  595 doi:10.1086/519795 (2007).
- 596 50 Gabriel, S. B. *et al.* The structure of haplotype blocks in the human genome. 597 *Science* **296**, 2225-2229, doi:10.1126/science.1069424 (2002).
- 598
- 599 Acknowledgements
- 600 This work has been supported through Consejería de Transformación Económica, Industria,
- 601 Conocimiento y Universidades of the regional government of Andalucía cofounded by the
- 602 European Union through European Regional Development Fund (FEDER, CV20-10150), Consejo
- 603 Superior de Investigaciones científicas (CSIC-COV19-016/202020E155) and Junta de Castilla y León
- 604 (Proyectos COVID 07.04.467B04.74011.0 and IBGM excellence programme CLU-2029-02). G.B. is
- 605 supported by the Instituto de Salud Carlos III (ISCIII, Spanish Health Ministry) through the Sara
- 606 Borrell subprogram (CD18/00153). The authors would like to particularly express their gratitude to
- 607 the patients, nurses and many others who helped directly or indirectly in the consecution of this
- 608 study.

- 609 Author information
- 610 Contributions
- 611 MEAR and GB designed the study; SRR, BS and DB recruited the patients, performed their clinical
- 612 assessment, and obtained the samples; CAD performed genotyping and DNA methylation
- 613 profiling; **MMB** performed genotype data curation, imputation and processing; **GB** performed DNA
- 614 methylation data curation and processing; **GB and EC** performed data analyses; **GB, EC, MMB and**
- 615 MEAR discussed and interpreted the results; and GB and MEAR wrote the entire manuscript. All
- 616 authors approved of the content of the manuscript.
- 617 Corresponding authors
- 618 Correspondence to Guillermo Barturen or Marta E. Alarcón Riquelme
- 619 Ethics declarations
- 620 Competing interests
- 621 The authors declare no competing interests.
- 622 Figures



624 Figure 1: COVID19 severity correlates with an increase in blood neutrophil proportion and 625 epigenetic changes in genes related with the innate immune response. (A) Methylome 626 deconvoluted blood cell proportions are plotted by cohort (left panel discovery, right panel 627 validation) and severity group (blue, negative SARS-CoV2 lab tested individuals; yellow, positive 628 individuals with mild symptoms and red, positive individuals with severe symptoms). Paired 629 differences were assessed by means of linear regression analysis (age and gender were included as covariates) and significance values plotted by pairs (p-value < 0.05, p-value < 0.01 and p-value < 630 631 1e-5). (B) Venn diagram with the number of significant shared DMCs across the differential 632 analysis performed (the number of annotated genes are included in parentheses). (C) Combined 633 manhattan plots are shown for the differential analysis that share DMCs, hypermethylated and 634 hypomethylated DMCs are divided into upper and lower side of the manhattan plot respectively. 635 Genes annotated for the shared DMCs are depicted, including, in parentheses their co-localization 636 with the annotated gene (TSS, Transcription Start Site: Body, gene body). Severe vs negative 637 (blue), mild vs negative (green), severe vs mild (vellow) and pseudotime longitudinal analysis (red).





639 Figure 2: COVID19 DNA methylation changes regulate autoimmune related functional pathways 640 and associate with environmental respiratory related traits. (A) Top 10 significant reactome 641 database pathways (p-value < 0.01) are shown by differential analysis. (B) Number of DMCs with 642 significant interactions for each deconvoluted cell-type proportion (red, B-cells; blue, CD4+ T-cells; 643 orange, CD8+ T-cells; purple, monocytes; blue, neutrophils and green, NK-cells) are split into 644 hypermethylated (upper panels) and hypomethylated (lower panel) and divided into the 645 differential analysis. (C) EWAS traits enrichments (p-value < 1e-10) for each differential analysis 646 are shown (MethBank database).



647

648 Figure 3: Epigenetic changes in CpGs associated with environmental respiratory traits 649 differentiate COVID19 progression and mild cases from autoimmune disorders. (A) Hyerarchical 650 clustering of methylation DMCs for both discovery and validation cohorts (Ward's hierarchical 651 agglomerative clustering with Pearson correlation as distance is used). Individual methylation 652 values are averaged by severity from severe cases (top), mild cases (middle) to negative lab tested 653 SARS-CoV2 (bottom). The annotations in the upper part of the plot refer to the analysis to which 654 each CpG is differentially methylated (black). Four CpG modules highly replicated between cohorts, were selected from the hierarchical clustering: S.Ho (Hypomethylated with the severity), 655 656 S.He (Hypermethylated with the severity), M.Ho (Hypomethylated in mild compared with severe 657 patients) and M.He (Hypermethylated in mild compared with severe patients and healthy 658 controls). (B) Reactome significant pathways by CpG module (p-value < 0.01) are shown. (C) 659 MethBank EWAS trait enrichment by CpG module (p-value < 1e-10) are shown. (D) Significant 660 overrepresentation of transcription factor binding site prediction (HOMER, p-value < 0.001) is 661 depicted by CpG module. (E) Average log2FC Pearson correlations between COVID19 severity 662 groups and seven different systemic autoimmune conditions (SLE, systemic lupus erythematosus; 663 RA, rheumatoid arthritis; pSjS, primary Sjögren's syndrome; SSc, systemic sclerosis; MCTD, mixed

664 connective tissue disease; PAPs, primary antiphospholipid syndrome and UCTD, undifferentiated665 connective tissue disease). DMCs are grouped by CpG modules.



666

667 Figure 4: Genetics contributes differentially to progressive and mild specific DNA methylation 668 changes. (A) Genetic contribution in terms of the fraction of the variance explained (heritability, 669 h2) of individual CpG methylation changes is shown by DNA methylation module. Statistical 670 differences are assessed by means of Wilcoxon test p-values. (B) Three significant mQTLs 671 regulating DNA methylation levels are shown divided by severity group and genotype. From left to 672 right, a common mQTL for all three severity groups in the S.Ho module, a positive specific mQTL 673 and a mild specific mQTL for M.He module are depicted. (C) Fraction of mQTL categories are 674 plotted by module and for all significant DMCs together. (D) Normalized MAFs for the largest mQTL categories (common mQTLs, positive specific mQTLs and mild specific mQTLs) represented 675 676 in at least three modules (S.Ho, S.He and M.He) are shown divided by severity group. Wilcoxon 677 test p-values were calculated between severity groups. (E) Enrichment of GWAS catalog and 678 COVID-19 Host Genetics Initiative associated SNPs are shown by CpG module (p-value < 1e-10).

## 679 Supplementary Figures



#### 680

681 **Supplementary Figure 1: Technical batch effect does not bias the methylation profiles.** t-SNE 682 analysis of the 10.000 most variable CpGs (based on the DNA methylation absolute deviation

683 mean) is shown colored by different variables: (A) severity groups, (B) neutrophil proportion, (C) 684 cohorts and (D) technical batch.



685

686 Supplementary Figure 2: Hypomethylated and hypermethylated DMCs are mostly enriched and 687 colocalized with gene regulatory elements, which tend to activate and inactivate in *cis* gene

688 expression levels. (A) Significant DMCs enrichment from each differential analysis across different 689 regulatory elements (annotatr R package). Hypermethylated and hypomethylated DMCs are 690 divided into left and right panels, respectively. Each DMC is allowed to be annotated in more than 691 one of the following features: 1 to 5kb, region between 1-5kb upstream from the TSS; promoters, 692 region at less than 1kb upstream, from the TSS; 5' UTR region; first exon; CDS, protein coding 693 regions: exon: intron: exon-intron boundaries: intron-exon boundaries: 3' UTR region: intergenic. 694 not colocalized with any gene annotation; CGI, CpG island; CGI shores, at less than 2kb of a CGI; 695 CGI shelves, at 2-4kb of a CGI; interCGI, not colocalized with any CGI annotion; IncRNA genes, 696 GENCODE long non-coding gene annotation and enhancer, colocalized with FANTOM5 enhancer 697 database annotation. Enrichment score is defined as the log2FC between the fraction of 698 colocalized DMCs and the CpGs in the EPIC array. Significance was calculated by means of a Fisher 699 exact test (p-value < 0.05, p-value < 0.01 and p-value < 1e-5). (B) Fraction of colocalized DMCs 700 by differential analysis for ranked gene features obtained from the EPIC array annotation (each 701 DMC is assigned to one feature according to: TSS, transcriptions start site > 5' UTR > 3' UTR > Body, 702 gene body not in the previous features > Intergenic, not assigned to any gene).



703

504 Supplementary Figure 3: Interferon exhaustion in severe COVID-19 patients is not regulated by 505 DNA methylation changes. (A-F) DNA methylation z-scored levels for CpGs colocalized with 506 interferon gene signature promoters are shown by COVID severity group in discovery and 507 validation cohorts. Wilcoxon test *p*-values are depicted by pairs.



708

Supplementary Figure 4: Enriched pathway activity in the CpG modules follow DNA methylation changes at early SARS-CoV-2 samplings in the cell-types with significant interactions. Reactome CD209 signaling (A), interferon alpha/beta signaling (B), FCGR3A-mediated phagocytosis (C) and PIP3 activates AKT signaling (D) activities were calculated per individual with ssgsea R package and grouped by COVID-19 severity groups at early and late samplings (>11 days after first symptoms) for B-cells, CD8+ T-cells and Neutrophils. Activities were plotted for two randomly selected subsets of 2500 cells, 500 cells per group. Wilcoxon test *p*-values are depicted against healthy controls.



#### 716

517 Supplementary Figure 5: Progressive hypomethylation during COVID-19 severity CpG module 518 (S.Ho) is composed of two different functional signatures. (A) logFC correlation plots for severe 519 and mild COVID-19 cases against two interferon related diseases (MCTD and pSjS) and two non-520 interferon related diseases (RA and SSc) are shown. Correlation coefficients and *p*-values are 530 shown by pairs. (B) logFC correlation plots without strongest hypomethylated CpGs are shown.



#### 722

723 Supplementary Figure 6: Genetic and non-genetic DNA methylation explained variance analyses.

(A) Genetic heritability correlation between two independent methods is shown by CpG module

725 (Linear mixed-model variance decomposition and Linear mixed-model fitting with the

- 726 diagonalization trick were used). Correlation coefficients and *p*-values are depicted by module. (B)
- 727 Genetic heritability correlation between linear mixed-model variance decomposition with and

- 728 without fixed effect covariates (SARS-CoV-2 infection, gender and age) is plotted. Correlation
- 729 coefficients and *p*-values are depicted by module. (C) Fraction of DNA methylation variance
- raction of CpGs by module (D) Fraction of CpGs by module
- associated with at least one SNP is shown.

#### 732 Tables

Discovery (10 Technical Batches)							Validation (3 Technical Batches)				
	#	Age	Gender	Hospitalized	Deceased	#	Age	Gender	Hospitalized	Deceased	
Negative	47	63 ± 21	20 (43%)	-	-	54	67 ± 20	27 (50%)	-	-	
Mild	269	$67 \pm 15^{*}$	126 (47%)	216 (80%)*	-	91	$61\pm18^{*}$	48 (53%)	87 (96%) <sup>*</sup>	-	
Severe	98	76 ± 14 <sup>*</sup>	126 (47%)	98 (100%)	84 (86%)	15	$64 \pm 18^{*}$	126 (47%)	15 (100%)	10 (67%)	

733

734 **Table 1: Cohorts' demographic and clinical information.** Number of individuals (#), age average ± standard deviation 735 (Age), number and percentage of males (Gender), hospitalized individuals (Hospitalized) and deceased individuals

(Age), number and percentage of males (Gender), hospitalized individuals (Hospitalized) and deceased individuals
 (Deceased) are shown by severity group and cohort. (\*) Discovery and validation cohorts showed significant differences

737 in terms of age in mild and severe groups (Mann-Whitney U test *p*-value < 0.05) and also in terms of numbers of

hospitalized mild symptoms patients (Fisher exact test < p-value 0.05).





-log10(p-value)





Prostate specific antigen measurement

Creatinine measurement

Rheumatoid arthritis



M.He - Positive specific mQTL CCDC92 / 12:124400105:AC:A



1.00

0.75

0.50

S.Ho

S.He

M.He



Negative

Mild

Severe

M.He - Mild specific mOTL



40

80

-log10(p-value)

120



С







Colocalization annotations

Gene annotationsCpG island annotationsOther annotations



Enrichment score













**B**-cells



CD8+ T-cells

Subsample 2

0.42

0.035

0.1

<2.2e-16

2<u>.2e-</u>16

1.3e-06

0.06

0.13

Subsample 1

0.002

0.02

0.0002

<2.2e-16

2e-16

4.9e-07

0.0006

0.97

0.4

0.2

0.0

-0.2

0.4

0.2

0.0

-0.2

## **Neutrophils**



#### **B-cells**



#### CD8+ T-cells Subsample 2 Subsample 1

## **Neutrophils**



## **B**-cells



## CD8+ T-cells



## **Neutrophils**



#### **B**-cells





## Subsample 1



## Neutrophils



D





0.00

MCTD vs Mild (R = 0.45, *p*-value = 0.0011) pSiS vs Mild (R = 0.48, p-value = 0.0005)RA vs Mild (R = -0.07, *p*-value = 0.62) SSc vs Mild (R = -0.05, *p*-value = 0.74)

MCTD vs Severe (R = 0.31, p-value = 0.032) pSjS vs Severe (R = 0.32, p-value = 0.023)RA vs Severe (R = 0.47, p-value = 0.0007) SSc vs Severe (R = 0.41, p-value = 0.004)

MCTD vs Mild (R = 0.1, *p*-value = 0.54) pSiS vs Mild (R = 0.22, p-value = 0.19)RA vs Mild (R = 0.0024, *p*-value = 0.99) SSc vs Mild (R = -0.097, *p*-value = 0.57)

MCTD vs Severe (R = 0.044, p-value = 0.8) pSjS vs Severe (R = 0.058, p-value = 0.73) RA vs Severe (R = 0.44, p-value = 0.0059) SSc vs Severe (R = 0.3, p-value = 0.07)

